Atika Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Atika Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-81,300	Closed	-$4.6M	–	98
2025 Q3	$4.6M	Sell	81,300 -65,300	-45%	-$2.95M	0.37%	62
2025 Q2	$6.4M	Buy	+146,600	New	+$5.05M	0.64%	42
2025 Q1	–	Sell	-136,500	Closed	-$5.49M	–	80
2024 Q4	$5.49M	Buy	136,500 +39,500	+41%	+$1.78M	0.58%	61
2024 Q3	$4.59M	Buy	97,000 +5,000	+5%	+$221K	0.47%	63
2024 Q2	$2.75M	Sell	92,000 -10,000	-10%	-$346K	0.27%	77
2024 Q1	$4.1M	Buy	+102,000	New	+$3.65M	0.4%	73

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Atika Capital Management's KYMR Position: Q4 2025 in Review

Atika Capital Management sold out of Kymera Therapeutics (KYMR) in Q4 2025, closing a stake of 81,300 shares — an estimated $4.6M sold.

Atika Capital Management first reported a position in KYMR in Q1 2024 and held it in 6 quarters. The position peaked at $6.4M in Q2 2025. 254 funds tracked by Wall St. Rank hold KYMR as of Q4 2025.

Atika Capital Management reported no remaining Kymera Therapeutics position as of Q4 2025 after selling out during the quarter.
Atika Capital Management sold 81,300 Kymera Therapeutics shares in Q4 2025, an estimated $4.6M.
Atika Capital Management first reported a position in Kymera Therapeutics in Q1 2024 and held it in 6 quarters.
Atika Capital Management's Kymera Therapeutics position peaked at $6.4M in Q2 2025.
254 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2025.

Based on Atika Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.